PuSH - Publikationsserver des Helmholtz Zentrums München

Keuper, M. ; Häring, H.-U. ; Staiger, H.

Circulating FGF21 levels in human health and metabolic disease.

Exp. Clin. Endocrinol. Diabet. 128, 752-770 (2020)
Postprint DOI PMC
Open Access Green
Human fibroblast growth factor 21 (FGF21) is primarily produced and secreted by the liver as a hepatokine. This hormone circulates to its target tissues (e. g., brain, adipose tissue), which requires two components, one of the preferred FGF receptor isoforms (FGFR1c and FGFR3c) and the co-factor betaKlotho (KLB) to trigger downstream signaling pathways. Although targeting FGF21 signaling in humans by analogues and receptor agonists results in beneficial effects, e. g., improvements in plasma lipids and decreased body weight, it failed to recapitulate the improvements in glucose handling shown for many mouse models. FGF21's role and metabolic effects in mice and its therapeutic potential have extensively been reviewed elsewhere. In this review we focus on circulating FGF21 levels in humans and their associations with disease and clinical parameters, focusing primarily on obesity and obesity-associated diseases such as type-2 diabetes. We provide a comprehensive overview on human circulating FGF21 levels under normal physiology and metabolic disease. We discuss the emerging field of inactivating FGF21 in human blood by fibroblast activation protein (FAP) and its potential clinical implications.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
Schlagwörter Hepatokine ; Metabolic Disease ; Obesity ; Diabetes; Growth-factor 21; Fibroblast Activation Protein; Nonalcoholic Fatty Liver; Ppar-alpha Activation; Brown Adipose-tissue; Y Gastric Bypass; Beta-klotho; Serum Concentrations; Glucose-metabolism; Factor-21 Levels
ISSN (print) / ISBN 0947-7349
e-ISSN 1439-3646
Zeitschrift Experimental and Clinical Endocrinology & Diabetes
Quellenangaben Band: 128, Heft: 11, Seiten: 752-770 Artikelnummer: , Supplement: ,
Verlag Thieme
Verlagsort Stuttgart
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes Research and Metabolic Diseases (IDM)